FDA actions in brief
FDA approved ranolazine extended-release tablets (Ranexa, CV Therapeutics) on January 31, 2006, for the treatment of chronic angina. A more thorough review of the agent will appear in the FDA Drug Approvals section of Formulary's March issue.
FDA approved ranolazine extended-release tablets (Ranexa, CV Therapeutics) on January 31, 2006, for the treatment of chronic angina. A more thorough review of the agent will appear in the FDA Drug Approvals section of Formulary's March issue.
An expanded indication was approved for bromfenac ophthalmic solution (Xibrom, Ista) to include the treatment of pain following cataract surgery.
Aprepitant (Emend, Merck) was approved to be used in combination with other antiemetic drugs to prevent nausea and vomiting associated with moderately emetogenic chemotherapy treatment.
The estradiol/levonorgestrel transdermal patch (Climara Pro, Berlex) was approved for the prevention of postmenopausal osteoporosis.
FDA approved lenalidomide (Revlimid, Celgene) for the treatment of patients with transfusion-dependent anemia resulting from low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
